Biologic Therapeutic Drugs: Technologies and Global Markets

Report Scope

This report provides an overview of the global biologic therapeutic drug market and analyzes market trends. It includes global revenue ($U.S. millions) for base year data for 2023 and estimated data for 2024. The forecast period is 2024 through 2029. The market is segmented based on product type, application, source and region. By product, the market is segmented into monoclonal antibodies, vaccines, peptide hormones, cell and gene therapies and others. By source, it is segmented into mammalian, microbial and others. By application, the market is segmented into oncology, autoimmune diseases, infectious diseases and others. The regions covered in this study are North America, Europe, Asia-Pacific, Middle East and Africa, and South America, focusing on the major countries in these regions. The North American region includes the U.S., Canada and Mexico. Europe includes Germany, the U.K., Italy, France, Spain and the Rest of Europe; Asia-Pacific includes China, Japan, India, South Korea and the Rest of Asia-Pacific.

The report focuses on the significant driving trends and challenges that affect the market and vendor landscape. It analyzes corporate environmental, social and governance (ESG) developments and discusses emerging technologies related to the market.

The report concludes with an analysis of the competitive landscape, which provides the ranking and share of key players in the global biologic therapeutic drug market. It also has a section dedicated to company profiles that covers such details as overview, key financials, product portfolio and recent developments of key market players.

Report Includes

• 49 data tables and 58 additional tables
• An overview of the current and future global markets for biologic therapeutic drugs and technologies
• An analysis of the global market trends, with market revenue data from 2021 to 2023, estimates for 2024, and projected CAGRs through 2029
• Estimates of the size and revenue prospects of the global market, along with a market share analysis by product type, application, source and region
• Facts and figures pertaining to market dynamics, technological advances, regulations, and the impact of macroeconomic factors
• Evaluation of the ongoing clinical trials and R&D activity for biologics production
• A look at the key drugs on the market and recent approvals, sales statistics and past performance of the top-selling biologics
• An analysis of patents, emerging trends and other developments in the industry
• Analysis of the industry structure, including companies’ market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
• Company profiles of major players within the industry, including Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Pfizer Inc., and Bristol-Myers Squibb Co.

Companies Mentioned

Abbvie Inc.
Amgen Inc.
Astrazeneca
Bristol-myers Squibb Co.
Eli Lilly And Co.
F. Hoffmann-la Roche Ltd.
Gilead Sciences Inc.
Gsk Plc.
Johnson & Johnson Services Inc.
Merck & Co. Inc.
Novartis Ag
Novo Nordisk A/S
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Sanofi